Complex common diseases are a significant burden for our societies and demand not only preventive measures but also more effective, safer, and more affordable treatments. The whole process of the current model of drug discovery and development implies a high investment by the pharmaceutical industry, which ultimately impact in high drug prices. In this sense, drug repurposing would help meet the needs of patients to access useful and novel treatments. Unlike the traditional approach, drug repurposing enters both the preclinical evaluation and clinical trials of the compound of interest faster, budgeting research and development costs, and limiting potential biosafety risks. The participation of government, society, and private investors is needed to secure the funds for experimental design and clinical development of repurposing candidates to have affordable, effective, and safe repurposed drugs. Moreover, extensive advertising of repurposing as a concept in the health community, could reduce prescribing bias when enough clinical evidence exists, which will support the employment of cheaper and more accessible repurposed compounds for common conditions.

复杂的常见疾病是我们社会的重大负担，不仅需要预防措施，而且还需要更有效，更安全和更实惠的治疗。当前药物发现和开发模型的整个过程意味着制药行业的大量投资，最终影响了高昂的药物价格。从这个意义上讲，重新调整药物用途将有助于满足患者获得有用且新颖的治疗方法的需求。与传统方法不同，重新利用药物的目的是更快地进入目标化合物的临床前评估和临床试验，从而为研究和开发成本编入预算，并限制潜在的生物安全风险。政府，社会的参与，并且需要私人投资者来确保资金用于实验设计和临床开发，从而使候选药物具有可负担，有效和安全的重新用途药物。此外，在健康界广泛宣传将重新使用作为概念的广告，可以在存在足够的临床证据时减少处方偏见，这将支持在普通情况下使用更便宜和更易获得的重新用途的化合物。